

- Acute febrile illness, 779
 approach to the patient, 779
 clinical presentations of, 764, 780t, 781–783
 diagnostic workup in, 779
 history in, 779
 physical examination in, 779
 rashes associated with, 25e-1
 treatment of, 779–781, 780t
- Acute febrile neutrophilic dermatosis. *See* Sweet syndrome
- Acute generalized eruptive/exanthematous pustulosis (AGEP)
 clinical features of, 132t, 384t
 pustular lesions, 356, 382, 382f
 rash, 25e-12f, 132t
 differential diagnosis of, 135, 382
 drugs associated with, 382
 immune pathways of, 378t
 nondrug related causes of, 384t
- Acute HIV syndrome, 1228, 1249, 1249f. *See also* HIV infection
- Acute inflammatory demyelinating polyneuropathy (AIDP), 2695, 2695t, 2696t
- Acute intermittent porphyria (AIP), 2526
 clinical features of, 2522t, 2526, 2529, 2681
 diagnosis of, 2522t, 2529
 genetic considerations in, 2681
 global considerations in, 2521
 pathophysiology of, 2522f, 2681
 treatment of, 367e-3, 2529–2530
 unsafe drugs in, 2526, 2527–2529t
- Acute interstitial nephritis (AIN), 1856
 allergic, 1804, 1857, 1857f
 clinical features of, 62e-10f, 289t, 1806t, 1856, 1857
 in crystal deposition disorders, 1858–1859
 diagnosis of, 289t, 1806t
 etiology of, 1856t
 granulomatous, 1857f, 1858
 hyperkalemia in, 307
 hypovolemia in, 297
 idiopathic, 1858
 IgG4-related, 391e-2, 1858
 infection-associated, 1858
 in light chain cast nephropathy, 62e-7f, 1859, 1859f
 in lymphomatous infiltration of the kidney, 1859
 in obstructive tubulopathies, 1858–1859
 renal biopsy in, 62e-10f
 in Sjögren's syndrome, 1857
 in SLE, 1858. *See also* Lupus nephritis
 treatment of, 1857f, 1857t
 in tubulointerstitial nephritis with uveitis, 1857–1858, 1858f
- Acute interstitial pneumonia (Hamman-Rich syndrome), 1712
- Acute kidney injury (AKI), 1799
 adaptive response to, 333e-5
 after liver transplantation, 2072
 approach to the patient, 290f, 291
 clinical features of, 289t, 1805, 1806t
 fluid volume disturbances, 297
 hyperkalemia, 304, 307
 hyponatremia, 299
 complications of, 1808–1809
 anemia and bleeding, 1809, 1810
 fluid volume disturbances, 1808, 1810
 hyperkalemia, 1808
 hyperphosphatemia, 1807, 1808–1809, 1810
 hypocalcemia, 1807
 malnutrition, 1809, 1810
 metabolic acidosis, 1808, 1810
 uremia, 1808
 in critically ill patient, 1735
 diagnosis of
 biomarkers, 1808
 blood laboratory findings, 291t, 1805, 1806t, 1807
 history and physical examination, 1805
 imaging, 1808
 renal biopsy, 62e-10f, 1808
 renal failure indices, 1807–1808
 urine findings, 291t, 1805, 1806t, 1807f
 epidemiology of, 1799
 etiology and pathophysiology of
 envenomation, 2737
 hypokalemia, 307
 intrinsic, 292, 1800, 1800f, 1802f
 ischemia-associated, 292, 1801–1802, 1803f, 1806t
 nephrotoxin-associated, 292, 1803–1804, 1806t
 postrenal, 291–292, 1804–1805, 1804f, 1806t
 prerenal, 291, 1800–1801, 1800f, 1801f, 1806t
 sepsis-associated, 1755, 1806t
 uric acid nephropathy, 431e-4, 431e-5
 global considerations in, 1799
 incidence of, 1799
 in leptospirosis, 1144
 maladaptive response to, 333e-5
 in malaria, 1374, 1374t, 1381
 preconditioning and, 333e-3–4, 333e-4t
 prevention of, 1809
 prognosis of, 1811
 in sarcoidosis, 2208
 in scleroderma renal crisis, 62e-9f, 2158, 2162, 2164
 in shock, 1746
 in transplant recipient, 1829
 treatment of
 in cirrhosis and hepatorenal syndrome, 1809–1810
 dialysis indications and modalities, 1810–1811
 intrinsic, 1810
 postrenal, 1810
 prerenal azotemia, 1809
 principles of, 1809, 1809t
 supportive measures, 1809t, 1810
- Acute lung injury (ALI). *See also* Acute respiratory distress syndrome (ARDS)
 pathophysiology of, 1736, 1737f
 in shock, 1746
 transfusion-related, 138e-5
 ventilator-induced, 1738
- Acute lymphoid leukemia (ALL)
 approach to the patient, 699–700
 classification of, 695, 695t
 epidemiology of, 695, 696f
 etiology of, 695
 genetic considerations in, 101e-3t, 699t
 hyperleukocytosis in, 1793
 immunology of, 698f
 infections in, 484t, 485, 486f, 486t, 488, 489
 late consequences of, 622, 624t
 lymphadenopathy in, 408
 peripheral blood smear in, 81e-9f
 precursor B cell, 701, 701f
 precursor T cell, 702t, 707
 prevention of, 643
 prognosis of, 700
 treatment of, 103e-22, 139e-5–6, 139e-5t
- Acute megakaryoblastic leukemia, 135e-7
- Acute motor axonal neuropathy (AMAN), 2695, 2695t, 2696t
- Acute motor sensory axonal neuropathy (AMSAN), 2695, 2695t, 2696t
- Acute mountain sickness (AMS), 476e-1–3, 476e-2t
- Acute myeloid leukemia (AML), 678. *See also* Acute promyelocytic leukemia (APL)
 cancer stem cells in, 102e-11
 classification of, 678–679, 679t
 clinical features of, 681
 diseases associated with, 678
 etiology of, 678
 genetic considerations in, 101e-2t, 373e-5, 679, 679t
 hyperleukocytosis in, 1793
 incidence of, 678
 infections in, 484t, 486t, 488, 685–686
 monocytopenia in, 422
 with mutated CEBPA, 679
 with mutated nucleophosmin, 679
 myelodysplasia and, 669
 peripheral blood smear in, 81e-9f, 681, 682f
 pretreatment evaluation of, 681–682, 683t
 prognosis of, 679–681, 680t
 as second malignancy in cancer survivors, 623, 678
 skin manifestations of, 366, 369
 treatment of
 agents under study for, 685t
 algorithm for, 682–684, 684f
 HSCT, 139e-5, 139e-5t, 684–685
 late consequences of, 624t
 postremission therapy, 684
 relapse, 686
 supportive care, 685–686
- Acute myelomonocytic leukemia, 237, 239t
- Acute myocardial infarction (AMI). *See* Myocardial infarction (MI)
- Acute necrotic collection, pancreatic, 2093t
- Acute necrotizing myopathy, 614t, 619, 1784
- Acute nephritic syndromes, 1835, 1835t, 1837
 ANCA small vessel vasculitis, 1835t, 1840
See also Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome); Granulomatosis with polyangiitis (Wegener's); Microscopic polyangiitis
 antglomerular basement membrane disease. *See* Antiglomerular basement membrane (anti-GBM) disease
 cryoglobulinemia. *See* Cryoglobulinemia
 endocarditis-associated glomerulonephritis, 1835t, 1837–1838
 Goodpasture's syndrome. *See* Goodpasture's syndrome
 IgA nephropathy. *See* IgA nephropathy
 IgA vasculitis. *See* IgA vasculitis (Henoch-Schönlein)
 lupus nephritis. *See* Lupus nephritis
 membranoproliferative glomerulonephritis. *See* Membranoproliferative glomerulonephritis
 poststreptococcal glomerulonephritis. *See* Poststreptococcal glomerulonephritis
 renal biopsy in, 62e-1–6f
- Acute pancreatitis, 2091
 in alcohol use disorder, 2091, 2725
 approach to the patient, 2086, 2092
 clinical features of, 2094
 abdominal pain, 106, 106t, 2092
 acute kidney injury, 1803
 fat necrosis, 366
 hypocalcemia, 2482
 hypovolemia, 298
 nausea and vomiting, 258
 complications of, 2096–2097, 2097t
 diagnosis of
 comparison of imaging methods, 2087t, 2088–2089, 2094–2095
 CT, 2093t, 2094f, 2095f
 endoscopy, 1899, 2087t
 ERCP, 2095f
 laboratory tests, 2087, 2087t, 2092–2093
 differential diagnosis of, 2093
 drug-related, 1273, 2092
 epidemiology of, 2086
 etiology of, 2091–2092, 2091t
 gallstone, 1893–1894
 genetic considerations in, 2092
 in HIV infection, 1258, 2097–2098
 incidence of, 2091
 interstitial, 2092, 2093t, 2095
 mild, 2094
 morphologic features of, 2093t
 necrotizing. *See* Necrotizing pancreatitis
 pancreatic enzyme activation in, 2092
 pathogenesis of, 2092
 phases of, 2093–2094
 physical examination in, 2092
 recurrent, 2097
 severe, 2094, 2094f, 2095f, 2095t
 treatment of, 2095–2096